Review of: Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA
For the next blog post in the series where I review papers published as part of the “Economics of Gene and Cell Therapies” in PharmacoEconomics, I will review: Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA. The paper can be found at the following…
Review of: Managed Entry Agreements for High‑Cost, One‑Off Potentially Curative Therapies: a framework and calculation tool to determine their suitability
For the next blog post in my series reviewing papers in the Economics of Cell and Gene Therapies collection in Pharmacoeconomics, I review ‘Managed Entry Agreements for High‑Cost, One‑Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability’ found at the following link: https://link.springer.com/article/10.1007/s40273-024-01433-4. This paper aimed to develop a framework to support…
Review of ‘Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States’
For the next blog post in the series where I review papers published as part of the “Economics of Gene and Cell Therapies” in PharmacoEconomics, I will review: ‘Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States’ found at the following link: https://link.springer.com/article/10.1007/s40273-024-01385-9. Individuals…
All NFHealthEconomics posts
Check out all my blog posts:
https://nf-health-economics.com/author/nfhealtheconomics/
Follow My Blog
Get new content delivered directly to your inbox.
Nermina Ferizovic | Health Economics Expert 